Shigeto Kanada

Azelnidipine and Amlodipine: a Comparison of Their Pharmacokinetics and Effects on Ambulatory Blood Pressure.

Kizuku Kuramoto, Shûichi Ichikawa, Aizan Hirai et al. · Hypertension Research · 2003 · 112 citations · Full text

Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in <scp>J</scp> apanese individuals with type 2 diabetes: <scp>A</scp> randomized, open‐label, 3‐arm parallel comparative, exploratory study

Daisuke Yabe, Masahiro Iwasaki, Hitoshi Kuwata et al. · Diabetes Obesity and Metabolism · 2016 · 67 citations · Full text

Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in <scp>J</scp> apanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study

Rimei Nishimura, Takeshi Osonoi, Shigeto Kanada et al. · Diabetes Obesity and Metabolism · 2015 · 49 citations · Full text

Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

Yoshiharu Horie, Shigeto Kanada, Hirotaka Watada et al. · Clinical Therapeutics · 2011 · 45 citations

Diabetes Management, Diabetes, Pharmacology +6

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in <scp>J</scp>apanese patients with type 2 diabetes mellitus

Shigeto Kanada, Kazuki Koiwai, Atsushi Taniguchi et al. · Journal of Diabetes Investigation · 2013 · 42 citations · Full text